(PharmaNewsWire.Com, July 06, 2017 ) Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 25, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5, 10 and 12 molecules, respectively.
Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease) . - The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles Abivax SA Altravax Inc Biological Mimetics Inc Bioneer Corp Biotron Ltd Emergent BioSolutions Inc Ennaid Therapeutics LLC GeneSegues Inc GlaxoSmithKline Plc Globavir Biosciences Inc Griffith University Hawaii Biotech Inc Humabs BioMed SA Immunotope Inc Indian Immunologicals Ltd Inovio Pharmaceuticals Inc Johnson & Johnson Kineta Inc Merck & Co Inc Molplex Ltd NanoViricides Inc Novartis AG NovaTarg Therapeutics Inc Panacea Biotec Ltd Plex Pharmaceuticals Inc Regeneron Pharmaceuticals Inc Sarepta Therapeutics Inc SIGA Technologies Inc Sun Pharma Advanced Research Company Ltd Takeda Pharmaceutical Company Ltd TechnoVax Inc Themis Bioscience GmbH Visterra Inc VLP Therapeutics LLC
Number of Products under Development for Dengue Fever, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Dengue Fever - Pipeline by Abivax SA, H1 2017 Dengue Fever - Pipeline by Altravax Inc, H1 2017 Dengue Fever - Pipeline by Biological Mimetics Inc, H1 2017 Dengue Fever - Pipeline by Bioneer Corp, H1 2017 Dengue Fever - Pipeline by Biotron Ltd, H1 2017 Dengue Fever - Pipeline by Emergent BioSolutions Inc, H1 2017 Dengue Fever - Pipeline by Ennaid Therapeutics LLC, H1 2017 Dengue Fever - Pipeline by GeneSegues Inc, H1 2017 Dengue Fever - Pipeline by GlaxoSmithKline Plc, H1 2017 Dengue Fever - Pipeline by Globavir Biosciences Inc, H1 2017 Dengue Fever - Pipeline by Griffith University, H1 2017 Dengue Fever - Pipeline by Hawaii Biotech Inc, H1 2017 Dengue Fever - Pipeline by Humabs BioMed SA, H1 2017 Dengue Fever - Pipeline by Immunotope Inc, H1 2017 Dengue Fever - Pipeline by Indian Immunologicals Ltd, H1 2017 Dengue Fever - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Dengue Fever - Pipeline by Johnson & Johnson, H1 2017 Dengue Fever - Pipeline by Kineta Inc, H1 2017 Dengue Fever - Pipeline by Merck & Co Inc, H1 2017 Dengue Fever - Pipeline by Molplex Ltd, H1 2017 Dengue Fever - Pipeline by NanoViricides Inc, H1 2017 Dengue Fever - Pipeline by Novartis AG, H1 2017 Dengue Fever - Pipeline by NovaTarg Therapeutics Inc, H1 2017 Dengue Fever - Pipeline by Panacea Biotec Ltd, H1 2017 Dengue Fever - Pipeline by Plex Pharmaceuticals Inc, H1 2017 Dengue Fever - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Dengue Fever - Pipeline by Sarepta Therapeutics Inc, H1 2017 Dengue Fever - Pipeline by SIGA Technologies Inc, H1 2017 Dengue Fever - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Dengue Fever - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Dengue Fever - Pipeline by TechnoVax Inc, H1 2017 Dengue Fever - Pipeline by Themis Bioscience GmbH, H1 2017 Dengue Fever - Pipeline by Visterra Inc, H1 2017 Dengue Fever - Pipeline by VLP Therapeutics LLC, H1 2017 Dengue Fever - Dormant Projects, H1 2017 Dengue Fever - Dormant Projects, H1 2017 (Contd..1) , H1 2017 Dengue Fever - Dormant Projects, H1 2017 (Contd..2) , H1 2017 Dengue Fever - Dormant Projects, H1 2017 (Contd..3) , H1 2017 Dengue Fever - Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
